



Non-profit Org.
U.S. Postage
PAID
Durham, NC
Permit No. 60



Program Description:

This annual event brings together experts in the field of hematologic malignancies to debate and discuss advances in treatment for these cancers, novel treatment options, and debate current treatment paradigms. There is a mini session focusing on the management of immunotherapy and its use in solid tumors as well.

Target Audience:

This educational activity is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, pharmacists, nurse practitioners, physician assistants, fellows, nurses, and other health care professionals interested in the treatment of patients with hematologic malignancies.

Learning Outcomes:

- Describe emerging data and recent advances in the management of hematologic malignancies
- Examine evidence-based rationale for opposing or alternative treatment, therapy or management options through lectures, case-based debates, moderated panel discussions, and a simulated tumor board
- Compare traditional and emerging treatment options in the management of hematologic disease
- Discuss the decision-making strategies used by advanced practice providers when evaluating toxicities and determining treatment changes

Presented by the Duke Cancer Network
in collaboration with Duke Cancer Institute

23rd Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies

April 21-23, 2023

The Westin Hilton Head Island Resort
South Carolina



Event Registration | Registration is limited. Please register early.

Event Registration: <https://bit.ly/DDHM23>

Physician	\$200
Fellow, Nurse, PA, and Pharmacist	\$150
Extra Exhibitor Fee (Must have a paid table)	\$750
Industry (Without a paid exhibitor table)*	\$1,500

Cancellation Policy:

Registration deadline is Friday, April 14, 2023. This registration fee will not be refunded if canceled after April 22, 2023.

*Includes industry nurses, pharmacists, and doctors



Hotel Reservations

The Westin Hilton Head Island
2 Grasslawn Avenue
Hilton Head, SC 29928

Hotel Reservations:
843-681-4000 Ref. Duke Debates 2023

<https://bit.ly/DDHM23WestinReservations>

Please make reservations by March 23, 2023.

Program Co-Chairs

- Harry Erba, MD, PhD** Professor of Medicine, Hematologic Malignancies and Cellular Therapy Director, Leukemia Program, Duke University Health System
- Linda Sutton, MD** Associate Chief Medical Officer, Duke Network Services Professor of Medicine, Duke University Health System

Content Directors

- Danielle Brander, MD** Assistant Professor of Medicine
- Cristiana Chase, DO** Assistant Professor of Medicine
- Therese Hennig, MPAS, PA-C** Physician Assistant
- Mitch Horwitz, MD** Professor of Medicine

Honored Guest Faculty

- Emily Curran, MD** Assistant Professor, University of Cincinnati
- Clifton Mo, MD** Assistant Professor of Medicine, Harvard Medical School; Senior Physician, Dana Farber Cancer Institute
- Mazyar Shadman, MD, MPH** Associate Professor, Medical Oncology, University of Washington; Associate Professor, Clinical Research Division, Fred Hutch; Attending Physician, Seattle Cancer Care Alliance
- Patrick Stiff, MD** Clinical Professor, Hematology/Oncology Loyola University Medical Center
- Richard Stone, MD** Chief of Staff, Dana Farber Cancer Institute Professor of Medicine, Harvard Medical School
- William Wierda, MD, PhD** Professor of Medicine, University of Texas MD Anderson Cancer Center
- Basem William, MD, MRCP(UK), FACP** Clinical Dir. Blood and Marrow Transplant Program and Cell Therapy Laboratory Ohio Health Riverside Methodist Hospital Bing Cancer Center Medicine; Henry Ford Hospital

Duke Faculty

- Donna Adams, MSN, ANP-BC, OCN** Nurse Practitioner
- Taewoong Choi, MD** Assistant Professor of Medicine
- Katharine Ciarrocca, DMD, MSEd** Associate Professor of Plastic, Maxillofacial, and Oral Surgery; Associate Professor, Head and Neck Surgery and Communication Sciences
- Ahmed Galal, MD** Professor of Medicine
- Tanya Helms, PA-C, R. Ph** Physician Assistant
- Yubin Kang, MD** Professor of Medicine
- Matthew McKinney, MD** Professor of Medicine
- Krista Rowe Nichols, RN, MSN, AOCNS** Clinical Specialist
- Kevin Oeffinger, MD** Professor of Medicine
- Lindsay Rein, MD** Assistant Professor of Medicine
- Emily Sellars, RN, MSN, ANP-C** Nurse Practitioner
- Andrea Sitlinger, MD** Assistant Professor of Medicine
- Scott Winkel, MHS, MSPH, PA-C** Physician Assistant



Duke Cancer Network
DUMC 3326, Durham, NC 27710



Accredited by



Joint Accreditation Statement

In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 12 MOC Part 2 points [and patient safety MOC credit] in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Credit Statement

Physicians: Duke University Health System Department of Clinical Education and Professional Development designates this live activity for a maximum of 14 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nursing: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 14 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 14 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-23-126-L04-P/T

Special Needs Statement

The Duke Cancer Network is committed to making its activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service. See the contact information below.

Contact/Questions

For questions, special needs, or sponsorship, please contact:
Beth Tanner, Duke Cancer Network
615 Douglas St. Suite 602, Durham, NC 27705
919-971-3627 | beth.tanner@duke.edu



23rd Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies April 21-23, 2023

Friday, April 21, 2023

12:00 p.m. Registration Opens

12:50 p.m. Welcome and Introductions: Therese Hennig, MPAS, PA-C*

Session 1: ABCs of Hematologic Malignancies Moderator: Therese Hennig, MPAS, PA-C*

12:55 p.m. Pre-Session Survey

1:00 p.m. Approach to Diagnosis of Blood Dyscrasias
Scott Winkel, MHS, MSPH, PA-C*

1:40 p.m. Personalized Therapeutics: Risk Stratification in Treatment
Selection for AML
Donna Adams, MSN, ANP-BC, ONC*

2:20 p.m. Break and Product Theater #1

3:00 p.m. What's all the Fuss with CAR-T? Does One Size Fit All?
Krista Rowe Nichols, RN, MSN, AOCNS*

3:30 p.m. Transplantation Overview
Tanya Helms, PA-C, R.Ph*

4:00 p.m. Decision Making for Individual Patients: CAR-T vs. Transplant
Ahmed Galal, MD*

4:30 p.m. Medication-Related Osteonecrosis of the Jaw (MRONJ): Update and
Management Strategies
Katharine Ciarrocca, DMD, MEd*

5:10 p.m. Closing Remarks



Saturday, April 22, 2023

7:00 – 7:50 a.m. ... Registration and Breakfast

Session 2: Leukemias / MDS / MPD Moderator: Harry Erba, MD, PhD*

7:55 a.m. Welcome and Pre-Session Survey

8:00 a.m. Keynote: First Things First – And Last: Onco-Primary Care in
Heme Malignancies
Kevin Oeffinger, MD*

8:45 a.m. Optimizing Outcomes for ALL: The Role of Risk Stratification and
Assessment of Minimal Residual Disease
Harry Erba, MD, PhD*

9:10 a.m. Case Presentation and Debate: Incorporating Transplant into the
Management of Standard Risk ALL Optimized Outcomes
Emily Curran, MD (Univ. of Cinn.) vs. Patrick Stiff, MD (Loyola)

10:00 a.m. Break and Product Theater #2

10:40 a.m. Case Presentation and Debate: The Evolving “Standard of Care” for
Myelofibrosis Optimizes Outcomes and Minimizes Toxicities
Lindsay Rein, MD* vs. Mitch Horwitz, MD*

11:30 a.m. Case Presentation and Debate: First Generation Agents Offer the Best
Overall Outcomes in FLT3 Mutated AML
Richard Stone, MD (Harvard) vs. Harry Erba, MD, PhD*

12:30- 1:25 p.m. ... Lunch and Time with Exhibitors

Session 3: Myeloma and Plasma Cell Dysplasias Moderator: Cristiana Chase, DO*

1:20 p.m. Pre-Session Survey

1:30 p.m. The Evolving Landscape of MM Treatment
Cristiana Chase, DO*

1:45 p.m. Debate: Transplantation Plays a Critical Role in Managing MM
Clifton Mo, MD (Harvard) vs. Taewoong Choi, MD*

2:30 p.m. Debate: Approach to Relapse After Response
Cristiana Chase, DO* vs. Yubin Kang, MD*

3:15 p.m. Break and Product Theater #3

3:55 p.m. Clinical Round Table with Case Presentation: AL Amyloidosis
Cristiana Chase, DO*, Clifton Mo, MD (Harvard) and Yubin Kang, MD*

4:45 p.m. Monoclonal Gammopathy of Renal Significance: Diagnosis and Next Steps
Scott Winkel, MHS, MSPH, PA-C*

5:00 p.m. Monoclonal Gammopathy of Renal Significance: Treatments
Taewoong Choi, MD*

5:15 p.m. Post Session Survey and Adjourn

Sunday, April 23, 2023

7:00 – 7:45 a.m. ... Registration and Breakfast and Product Theater #4

7:50 a.m. Welcome: Danielle Brander, MD*

7:55 a.m. Pre-Session Survey

Session 4: Lymphocytic Malignancies Moderator: Danielle Brander, MD*

8:00 a.m. Case Presentation and Debate: Combination Regimes are Superior to
Monotherapy with Novel Therapeutics in CLL
William Wierda, MD, PhD (MD Anderson) vs. Andrea Sitlinger, MD*

8:45 a.m. Case Presentation and Roundtable : Use of BTKi Should be Optimized
Before Moving to Alternatives
Danielle Brander, MD*, Andrea Sitlinger, MD*,
William Wierda, MD (MD Anderson)

9:30 a.m. Case Presentation and Debate: Is CAR-T a Better Option than Auto-
Transplant in Recurrent DLBCL Role of Transplant in Lymphoma, in the
Era of CAR-T; Identifying Best Candidates
Mazyar Shadman, MD, MPH (Fred Hutch) vs. Ahmed Galal, MD*

10:15 a.m. The Future of CAR-T
Ahmed Galal, MD*


10:35 a.m. Break

11:00 a.m. Case Presentation and Debate: Autologous Transplant in T-Cell Lymphoma
Basem William, MD, MRCP (UK), FACP vs. Matthew McKinney, MD*

11:40 a.m. Molecular Tumor Board: Individualized Therapy in Heme Malignancies:
Using Genetic and Molecular Profiling to Optimize Therapy
Matthew McKinney, MD*

12:20 p.m. Adjourn

*Denotes Duke Faculty



Special Thanks to our Sponsors

Platinum Sponsors

BeiGene, Eli Lilly, Genentech, Janssen

Gold Sponsors

BMS, GSK, Jazz, Pharmacyclics, Sanofi

Silver Sponsors

Abbvie, AstraZeneca, Servier

Bronze Sponsors

Acrotech, Adaptive Biotech, ADC Therapeutics, Astellas, Collectar, CTI Biopharma, DSI, Gilead, Incyte, Kite, Kyowa Kirin, Merck, Morophosys, Novartis, Pfizer, PharmaEssentia, Seagen